Monday, August 25, 2008

Recruiting for Clinical Trials

Map Legend
This is the last week of the month and same Brazilians have no money. Why not being volunteer in a clinical trial? The above map gives informations on clinical trials around the world.

If you, in US, know someone for the clinical trial below you can tell him to go to this page and give a try on Thalidomide:
"This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), August 2008

Sponsored by: Dana-Farber Cancer Institute
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00357500

RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide together with thalidomide, celecoxib, and fenofibrate works in treating young patients with relapsed or progressive cancer.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Unspecified Childhood Solid Tumor, Protocol Specific
Drug: celecoxib
Drug: cyclophosphamide
Drug: etoposide
Drug: fenofibrate
Drug: thalidomide
Phase II

U.S. FDA Resources

Study Type: Interventional
Study Design: Treatment

Official Title: Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer

Further study details as provided by National Cancer Institute (NCI):"

You can visit the site and there might have some other you can volunteer and make an extra-money. Gook Luck!

No comments: